---
schema_version: "secwatch.filing_event.v1"
accession: "0001100682-25-000041"
form_type: "8-K"
ticker: "CRL"
cik: "0001100682"
company_name: "CHARLES RIVER LABORATORIES INTERNATIONAL, INC."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:10:46.089649+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Charles River Q3 revenue $1.00B (-0.5% YoY); GAAP EPS $1.10, non-GAAP $2.43

## Summary
- Organic revenue declined 1.6%; DSA -3.1%, Manufacturing -5.1%, offset by RMS +6.5%.
- GAAP net income $54.4M ($1.10/diluted) vs $68.7M ($1.33) a year ago; non-GAAP net income $120.3M ($2.43) vs $133.7M ($2.59).
- GAAP operating margin improved to 13.3% (11.6% Q3 2024) on restructuring cost savings; non-GAAP margin dipped to 19.7% (19.9%).
- 2025 guidance narrowed: reported revenue growth (1.5%)-(0.5%) and non-GAAP EPS $10.10-$10.30, versus prior $9.90-$10.30.
- Management sees early positive signals but remains cautious; expects industry recovery to take time.

## SEC filing metadata
- accession: 0001100682-25-000041
- form_type: 8-K
- ticker: CRL
- cik: 0001100682
- company_name: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1100682/000110068225000041/0001100682-25-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1100682/000110068225000041/crl-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001100682-25-000041
- JSON: https://secwatch.observer/filing/0001100682-25-000041.json
- Plain text: https://secwatch.observer/filing/0001100682-25-000041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.